Editorials

Neurocysticercosis

BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7388.511 (Published 08 March 2003) Cite this as: BMJ 2003;326:511

Eradication of cysticercosis is an attainable goal

  1. Julio Sotelo, general director
  1. National Institute of Neurology and Neurosurgery, Neuroimmunology Unit, Insurgentes Sur 3877 DF, Mexico City 14269, Mexico

    Neurocysticercosis is a disease of large proportions; in most developing countries, with the exception of the Muslim world, neurocysticercosis is by far the main cause of epilepsy with a late onset and of hydrocephalus in adults.1 In the past 20 years two developments have drastically improved the gloomy picture that was associated with neurocysticercosis in the past: neuroimaging studies and the advent of effective cysticidal drugs. Computed tomography and magnetic resonance are now the cornerstone tools for diagnosing neurocysticercosis, and two drugs, albendazole and praziquantel, are inexpensive, effective cysticidals and are not toxic.2 Pharmacological treatment is now widely accessible and effective even in cases of giant cysticerci or ventricular cysts, which used to be the exclusive domain of neurosurgery.3

    However, a new paradox has emerged. Although drug treatment is inexpensive, neuroimaging is unaffordable for many patients in endemic areas. Immunodiagnostic tests using serum, which theoretically would represent a logical alternative for screening and diagnosis, have been abandoned in many neurological centres because of their poor reliability.4 Currently they …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe